J Korean Med Assoc.  2007 Apr;50(4):348-356. 10.5124/jkma.2007.50.4.348.

Bipolar Disorder

• Kwak KP

• KMID: 2184853
• DOI: http://doi.org/10.5124/jkma.2007.50.4.348

Abstract

Bipolar disorder is one of the most distinct syndromes in psychiatry. Bipolar I disorder affects approximately 1 percent of the population worldwide. About 50 percent of patients with bipolar illness have a family history of the disorder. Studies of twins suggest that the concordance rate of bipolar illness is between 40 percent and 80 percent in monozygotic twins. Although researchers have proposed myriad subtypes of depression, there are two major subtypes of disorder according to DSM-IV-TR: bipolar I and bipolar II. Bipolar I disorder is diagnosed on the basis of a single lifetime manic or mixed episode. Indeed, in one follow-up survey of tertiary care patients, depressive symptoms were more than three times as frequent as manic symptoms. Antidepressant monotherapy in an undiagnosed bipolar disorder patient can have devastating effects. So, clinical evaluation of a patient presenting with depression should always include the assessment for bipolar disorder. In addition to major episodes, it is important to pay attention to the course of subsyndromal and prodromal symptoms. Treatment options for bipolar disorder have rapidly expanded over the last decade. The literature supports the efficacy of a list of agents for the management of bipolar disorder, including lithium, valproate, lamotrigine, and carbamazepine, as well as the atypical antipsychotics olnazapine, risperidone, quetiapine, ziprasidone, and aripiprazole.

Keyword

Bipolar disorder; Manic depression; Bipolar depression; Bipolar spectrum disorder

MeSH Terms

Antipsychotic Agents
Aripiprazole
Bipolar Disorder*
Carbamazepine
Depression
Follow-Up Studies
Humans
Lithium
Quetiapine Fumarate
Prodromal Symptoms
Risperidone
Tertiary Healthcare
Twins, Monozygotic
Valproic Acid
Antipsychotic Agents
Carbamazepine
Lithium
Risperidone
Valproic Acid

Figure

• 

  Figure 1 Real course of bipolar disorder.

Reference

1. Diagnostic and Statistical Manual of Mental Disorders. 2000. 4th ed Text revision, ed. Washington DC: American Psychiatric Association.

2. Belmaker RH. Bipolar disorder. N Engl J Med. 2004. 351:476–486.

3. Sadock , Benjamin J, Sadock VA, editors. Kaplan & Sadock's comprehensive textbook of psychiatry. 2000. 7th ed. Philadelphia: Lippincott Williams & Wilkins;2.

4. Thase ME. Bipolar depression: issues in diagnosis and treatment. Harv Rev Psychiatry. 2005. 13:257–271.

5. Ghaemi SN, Ko JY, Goodwin FK. "Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry. 2002. 47:125–134.

6. Frank E, Swartz HA, Kupfer DJ. Interpersonal and social rhythm therapy: managing the chaos of bipolar disorder. Biol Psychiatry. 2000. 48:593–604.

7. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003. 64:161–174.

8. Boerlin HL, Gitlin MJ, Zoellner LA, Hammen CL. Bipolar depression and antidepressant-induced mania: a naturalistic study. J Clin Psychiatry. 1998. 59:374–379.

9. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, Solomon DA, Leon AC, Keller MB. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003. 60:261–269.

10. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002. 59:530–537.

11. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord. 2000. 59:S1. S5–S30.

12. Hirschfeld RM. Bipolar spectrum disorder: improving its recognition and diagnosis. J Clin Psychiatry. 2001. 62:S14. 5–9.

13. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE Jr, Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck PE Jr, Lewis L, McElroy SL, Post RM, Rapport DJ, Russell JM, Sachs GS, Zajecka J. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry. 2000. 157:1873–1875.

14. Jon DI, Bahk WM, Min KJ, Shin YC, Yoon BH, Cho HS, Chung SK, Ha KS. Korean Medication Algorithm for Bipolar Disorder 2006(I). Korean J Psychopharmacol. 2006. 17:349–361.

15. Coryell W, Endicott J, Maser JD, Mueller T, Lavori P, Keller M. The likelihood of recurrence in bipolar affective disorder: the importance of episode recency. J Affect Disord. 1995. 33:201–206.

16. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Maser J, Rice JA, Judd LL, Akiskal HS, Schettler PJ, Coryell W, Maser J, Rice JA, Solomon DA, Keller MB. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J Affect Disord. 2003. 73:19–32.

17. Ketter TA. Advances in Treatment of Bipolar Disorder. 2005. Washington DC: American Psychiatric Publishing;280.

18. Suppes T, Dennehy EB, Swann AC, Bowden CL, Calabrese JR, Hirschfeld RM, Suppes T, Dennehy EB, Swann AC, Bowden CL, Calabrese JR, Hirschfeld RM, Keck PE Jr, Sachs GS, Crismon ML, Toprac MG, Shon SP. Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry. 2002. 63:288–299.

19. Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, Sharma V, Beaulieu S. Guidelines Group, CANMAT. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord. 2006. 8:721–739.

20. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002. 159:S4. 1–50.

21. Ghaemi SN. New treatments for bipolar disorder: the role of atypical neuroleptic agents. J Clin Psychiatry. 2000. 14:33–42.

22. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999. 60:79–88.

23. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR. BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006. 26:600–609.

24. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003. 9:1079–1088.

25. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005. 162:1351–1360.

26. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J. Lamictal 606 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003. 60:392–400.